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Silver Medal Lecture
High-fat diet, muscular lipotoxicity and insulin resistance
Patrick Schrauwen
Department of Human Biology, Maastricht University, Wageningen Center for Food Sciences (WCFS) & Nutrition and
Toxicology Research Institute Maastricht (NUTRIM), PO Box 616, NL-6200 MD, Maastricht, The Netherlands
A high dietary fat intake and low physical activity characterize the current Western lifestyle.
Dietary fatty acids do not stimulate their own oxidation and a surplus of fat is stored in white
adipose tissue, liver, heart and muscle. In these organs intracellular lipids serve as a rapidly-
available energy source during, for example, physical activity. However, under conditions of
elevated plasma fatty acid levels and high dietary fat intake, conditions implicated in the
development of modern diseases such as obesity and type 2 diabetes mellitus, fat accumulation
in liver and muscle (intramyocellular lipids; IMCL) is associated with the development of
insulin resistance. Recent data suggest that IMCL are specifically harmful when combined with
reduced mitochondrial function, both conditions that characterize type 2 diabetes. In the
(pre)diabetic state reduced expression of the transcription factor PPARg co-activator-1a
(PGC-1a), which is involved in mitochondrial biogenesis, has been suggested to underlie the
reduced mitochondrial function. Importantly, the reduction in PGC-1a may be a result of low
physical activity, consumption of high-fat diets and high plasma fatty acid levels. Mitochon-
drial function can also be impaired as a result of enhanced mitochondrial damage by reactive
oxygen species. Fatty acids in the vicinity of mitochondria are particularly prone to lipid
peroxidation. In turn, lipid peroxides can induce oxidative damage to mitochondrial RNA,
DNA and proteins. The mitochondrial protein uncoupling protein 3, which is induced under
high-fat conditions, may serve to protect mitochondria against lipid-induced oxidative damage,
but is reduced in the prediabetic state. Thus, muscular lipotoxicity may impair mitochondrial
function and may be central to insulin resistance and type 2 diabetes mellitus.
Intramyocellular lipids: Mitochondrial function: Oxidative damage: Type 2 diabetes:
Insulin resistance
The prevalence of obesity continues to increase in affluent
societies. For example, in the USA the percentage of
individuals >20 years of age with obesity (defined as a
BMI of >30 kg/m2) increased from 13% in 1960 to 30% in
2000, according to the latest National Health and Nutrition
Examination Survey (Flegal et al. 2002). Moreover,
according to this survey the overall prevalence in individ-
uals >20 years with a BMI of >25 kg/m2, which is con-
sidered to represent overweight, was 64%. This increase
in the prevalence of obesity in adults has not only been
seen in affluent societies, but has also been observed
recently in developing countries. Even more dramatically,
the prevalence of obesity in US children between 6 and 19
years of age increased from 4% in the 1960s to 15% in
2000 (Ogden et al. 2002). Obesity increases the risk for a
number of health-threatening diseases and disorders, such
as type 2 diabetes mellitus, high blood pressure, high
cholesterol, asthma, arthritis and cardiovascular compli-
cations. In line with the increasing prevalence of obesity,
the incidence of type 2 diabetes mellitus has increased
dramatically. In 2003 about 194 million individuals, 5.1%
of the global population in the age-group 20–79 years,
were estimated to have diabetes. It is estimated that the
number of individuals suffering from type 2 diabetes
Abbreviations: IMCL, intramyocellular lipids; PGC-1a, PPARg coactivator-1a; ROS, reactive oxygen species; UCP, uncoupling protein.
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worldwide will be approximately 330 million in 2025, with
approximately 10% (472 million) of the global population
suffering from impaired glucose tolerance. The continuous
increase in the prevalence of type 2 diabetes contributes
considerably to illness and mortality rates.
Obesity, energy balance and fat balance
By definition, the development of obesity and overweight
is characterized by a positive energy balance. Numerous
investigations (Schutz et al. 1989; Bennett et al. 1992)
have shown that in the long term an imbalance between
energy intake and energy expenditure is reflected in a
positive fat balance. In the last 20–30 years many food
products have become available that are cheap, palat-
able and high in fat content. Since dietary fat is the most
energy-dense macronutrient, about 38 kJ/g (in comparison,
carbohydrate and protein only provide about 17 kJ/g), an
increase in dietary fat intake profoundly increases dietary
energy intake and thus results in a positive energy balance.
In addition, in human subjects there is evidence for a clear
substrate hierarchy for the utilization of macronutrients,
in which fat balance is least regulated. For example, the
human body responds only very slowly by increasing fat
oxidation when fat intake is increased (Thomas et al. 1992;
Schrauwen et al. 1997a), leading to a deposition of dietary
fat in the fat stores. On the other hand, the storage capacity
for carbohydrate and protein in the human body is limited
and therefore carbohydrate and protein oxidation are very
well and rapidly adjusted to their respective intake (Abbott
et al. 1988). As a consequence, a positive energy balance
will be reflected in a positive fat balance.
Fat oxidation on a high-fat diet
Although there is ample evidence that the adaptation of fat
oxidation to increased fat intake is slow in man, the reason
for this slow adaptation is relatively unknown. According
to the two-compartment model of Flatt (1987), whole-body
fat oxidation can be increased via an expansion of fat
mass, leading to increased plasma NEFA levels available
for oxidation. In this model the body is divided into two
compartments, fat mass and glycogen stores, and the oxi-
dation mixture of fatty acids and glucose depends on the
size of these two compartments. As the glycogen stores are
very limited in size, small changes in the size of the
glycogen stores will affect glucose oxidation. In contrast,
as the fat mass can be relatively unlimited in size, a large
expansion of fat mass is needed before changes in fat
oxidation will occur. This model can explain why the
addition of a surplus of fat to a single meal, which will not
result in a change in fat mass, does not affect fatty acid
oxidation rates, and why obese subjects have relatively
high fat oxidation. In fact, expansion of fat mass (obesity)
could be considered as an adaptation of the body to
increase fat oxidation to a level that matches a high dietary
fat intake. However, it has been shown (Schrauwen et al.
1997a) that healthy human volunteers who consume a
high-fat diet for 7 d, while being in energy balance, are
able to slowly increase their fat oxidation to a level that
equals the high-fat intake. As no substantial expansion of
fat mass can be expected after 7 d of a high-fat diet, these
results seem to contradict Flatt’s (1987) model. These
findings have, however, been explained in terms of the
changes in glycogen stores that may have occurred
(Schrauwen et al. 1997b, 1998). During the first days on a
high-fat diet, when fat oxidation does not equal fat intake,
subjects are in negative carbohydrate balance (carbo-
hydrate oxidation>carbohydrate intake), leading to a de-
crease in the body’s glycogen stores. According to Flatt’s
(1987) two-compartment model, a decrease in glycogen
stores would result in a decrease in glucose oxidation and
would therefore be another way to increase fat oxidation.
Indeed, it has been shown (Schrauwen et al. 1997b, 1998)
that lowering glycogen stores by exhaustive exercise
markedly improves the rate at which subjects are able to
adapt their fat oxidation to an increased fat intake.
In order to further investigate the mechanisms by which
fat oxidation increases on a high-fat diet, a more detailed
determination of fatty acid oxidation has been conducted in
subjects consuming high-fat diets (Schrauwen et al. 2000).
Interestingly, it was observed that the increase in fat oxi-
dation after 7 d of a high-fat diet is completely accounted
for by an increase in TAG-derived fatty acid oxidation.
Thus, using labelled fatty acids plasma-derived fatty acid
oxidation can be distinguished from the oxidation of
TAG-derived fatty acids (mainly intramyocellular lipids
(IMCL)). IMCL are small lipid droplets that are located in
the sarcoplasm and predominantly found in the vicinity of
mitochondria, suggesting that they may serve as a rapidly-
available energy source for the muscle. Using proton
magnetic resonance spectroscopy to quantify these IMCL
non-invasively, it has recently been shown (Schrauwen-
Hinderling et al. 2005) that the amount of IMCL is already
markedly increased after 7 d of a high-fat diet in healthy
lean subjects. In analogy with the model of Flatt (1987),
which predicts that an increase in body fat mass is needed
to increase whole-body fat oxidation, these combined
observations of an increased IMCL mass and increased
IMCL oxidation indicate that increases in IMCL content
are also needed to drive increased IMCL oxidation. Thus,
the slow rate at which fat oxidation adapts to increased
fat intake when a high-fat diet is consumed may also be
attributed to the time needed to increase IMCL content.
Interestingly, it has been found (Schrauwen et al. 2002c)
that when sedentary middle-aged subjects follow an en-
durance training programme for 3 months whole-body fat
oxidation increases, and again this increase is completely
accounted for by an increase in TAG-derived fatty acid
oxidation. In accordance with the earlier mentioned
hypothesis, endurance training is also known to increase
IMCL content (Goodpaster et al. 2001; Schrauwen-
Hinderling et al. 2006a), suggesting that similar mecha-
nisms may be involved in the training- and diet-induced
increase in fat oxidation.
Intramyocellular lipid and insulin sensitivity
As mentioned earlier, the steadily-increasing prevalence
of obesity is accompanied by a steady increase in the
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prevalence of type 2 diabetes mellitus. Central to the
aetiology of type 2 diabetes is insulin resistance, an early
detectable characteristic preceding the development of
full-blown and clinically-overt type 2 diabetes. Insulin
resistance indicates a state of reduced responsiveness of
the insulin-sensitive tissues to circulatory levels of insulin,
i.e. a reduced glucose disposal and impaired inhibition of
hepatic glucose output at a given concentration of insulin
(McGarry, 2002). A major contribution to whole-body
insulin resistance comes from the skeletal muscle, as
revealed by classical work by DeFronzo et al. (1981), who
have shown a 45% reduction in leg glucose uptake fol-
lowing a hyperinsulinaemic euglycaemic clamp in patients
with type 2 diabetes and a strong positive correlation
(r 0.70, P<0.001) between leg and total body glucose
uptake.
Evidence gathered in recent decades has pointed towards
an important causal role of disturbed fatty acid metabolism
in the development of type 2 diabetes mellitus. Not only
are plasma glucose levels increased in uncontrolled type 2
diabetes, but also plasma NEFA, and the storage of fatty
acids in non-adipose tissues such as pancreas, liver and
muscle is elevated in patients with type 2 diabetes (Schalch
& Kipnis, 1965). Moreover, a strong negative correlation
has been found between the level of IMCL and insulin
sensitivity in non-trained subjects (Perseghin et al. 1999),
and levels of IMCL are increased in first-degree relatives
of patients with type 2 diabetes who are insulin resistant,
but not diabetic (Jacob et al. 1999). These data suggest
that IMCL accumulation may be a primary factor in the
development of type 2 diabetes. Remarkably, this suggest-
ed role differs from the putative physiological function
of IMCL as an important energy source that drives
muscular fatty acid oxidation. On the other hand, the high
levels of IMCL in the endurance-trained state contradict
the suggestion that IMCL may have detrimental effects on
insulin sensitivity, as endurance training is well known to
improve whole-body and muscular insulin sensitivity. To
unravel this apparent paradox the molecular adaptations
that occur in skeletal muscle have been examined in sub-
jects who were either trained for 2 weeks or consumed a
high-fat diet for 7 d. As expected, both interventions
increased IMCL levels to a similar extent (Schrauwen-
Hinderling et al. 2006a,b). Furthermore, consistent with
the hypothesis that elevated IMCL levels may serve as an
important energy source, it has been found (Schrauwen-
Hinderling et al. 2006a) that after 2 weeks of endurance
training in previously untrained subjects there are already
molecular adaptations in skeletal muscle that point towards
an improved fat oxidative capacity. In contrast, however,
the consumption of a high-fat diet for 1 week is accom-
panied by molecular changes that would favour fat storage
in muscle rather than oxidation (Schrauwen-Hinderling
et al. 2005). These findings suggest that IMCL may be
increased for two different reasons: (1) a functional in-
crease, whereby IMCL serves as a rapidly-available energy
source; in these conditions (e.g. as with endurance training)
fat oxidative capacity improves, followed by the storage of
more muscular lipids that can serve as rapidly-available
energy source; (2) a pathophysiological increase, whereby
the increase in IMCL is merely the result of a continuous
over-supply of fat to the muscle and is not accompanied
by an increased fat oxidative capacity; in this condition
muscular fat accumulation results from passive uptake of
excessive fatty acids, and the increased IMCL content may
ultimately drive IMCL oxidation. Thus, in the latter con-
dition the increase in IMCL can be seen as an ‘adaptation’
to allow increased muscular fat oxidation when fat intake
is high, similar to the concept of obesity being an adapt-
ation to increase whole-body fat oxidation. However, as
with obesity, the ‘adaptive’ increase in IMCL in the latter
condition is accompanied by negative side effects, which is
indicated by the relationship between IMCL and insulin
resistance.
Thus, it can be deduced that high IMCL content is only
harmful in the absence of adaptations in oxidative capacity,
such as with high-fat diet consumption and/or type 2
diabetes mellitus. To examine this hypothesis a comparison
has been made of the IMCL content and mitochondrial
oxidative capacity in patients with type 2 diabetes and in
normoglycaemic controls matched for BMI (Schrauwen-
Hinderling et al. 2007). Thus, a 31P magnetic resonance
spectroscopy method was used to investigate in vivo
mitochondrial function by measuring the phosphocreatine
kinetics during recovery from exercise (Meyer, 1988;
Kemp & Radda, 1994). During exercise phosphocreatine
content decreases transiently but recovers rapidly after
exercise. In the post-exercise state phosphocreatine re-
synthesis is driven almost purely oxidatively (Sahlin et al.
1979) and the resynthesis rate reflects in vivo mitochon-
drial function (Kemp & Radda, 1994). It was found that
despite similar IMCL levels, phosphocreatine resynthesis
rate is reduced by approximately 50% in patients with type
2 diabetes, indicating mitochondrial dysfunction. Thus, the
combination of high IMCL and low oxidative capacity is
important in the aetiology of type 2 diabetes mellitus.
Along the same line of reasoning Goodpaster et al. (2001)
have suggested that fat oxidative capacity might be more
important than IMCL content in determining insulin
sensitivity, whereas Petersen et al. (2004) have reported
decreased mitochondrial function (oxidative capacity)
in the insulin-resistant offspring of patients with type 2
diabetes when compared with insulin-sensitive controls.
Together, these findings indeed point towards the impor-
tance of mitochondrial oxidative capacity in the aetiology
of type 2 diabetes. Although beyond the scope of the pre-
sent review, a functional explanation is provided by the
observation that lipid metabolites such as fatty acyl-CoA
or diacylglycerol are more likely to intervene with insulin
signalling than IMCL per se. Diacylglycerol is the inter-
mediate between fatty acyl-CoA, which can enter the
mitochondria for oxidation, and TAG, the form in which
lipids are stored in muscle. If an increase in IMCL is not
accompanied by a sufficiently increased fat oxidative
capacity (i.e. a low mitochondrial oxidative capacity),
levels of lipid metabolites will rise and interfere with
insulin signalling (for review, see Shulman, 2000).
What causes mitochondrial dysfunction?
Although the finding of a reduced mitochondrial oxidative
capacity in both first-degree relatives and patients with
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type 2 diabetes is intriguing, the mechanism underlying
this reduction remains to be determined. One likely
explanation for the mitochondrial dysfunction observed in
the (pre)diabetic state is a reduced expression of genes
involved in mitochondrial oxidative metabolism, as has
been observed in type 2 diabetes (Mootha et al. 2003; Patti
et al. 2003). Many of the oxidative genes are under tran-
scriptional control of PPARg coactivator-1a (PGC-1a),
which stimulates oxidative phosphorylation, mitochondrial
biogenesis and the generation of oxidative type 1 muscle
fibres (Lin et al. 2002). In addition to the down-regulation
of the so-called OXPHOS gene set, it has been shown that
the expression of PGC-1a itself is also reduced in patients
with type 2 diabetes (Mootha et al. 2003; Patti et al. 2003).
Strikingly, the same observations have been reported in
subjects who do not have type 2 diabetes, but have a
family history of type 2 diabetes (Patti et al. 2003).
Recently, these findings have been confirmed (M Mensink,
MKC Hesselink, AP Russell, G Schaart, J-P Sels and P
Schrauwen, unpublished results) in patients with type 2
diabetes, showing an approximately 60% reduction in
PGC-1a gene expression compared with BMI and age-
matched controls. Interestingly, it has been found (M
Mensink, MKC Hesselink, AP Russell, G Schaart, J-P Sels
and P Schrauwen, unpublished results) that treating these
patients with the anti-diabetic agent Rosiglitazone restores
muscular PGC-1a levels, along with an improvement in
muscular insulin sensitivity. In addition, it has been shown
(Russell et al. 2005) that acute exercise, which is well
known to improve muscular oxidative capacity and insulin
sensitivity, up regulates the expression of PGC-1a in
healthy subjects. Also, prolonged endurance training
increases PGC-1a protein content (Russell et al. 2003a).
These data indicate that PGC-1a may indeed play a crucial
role in the development of mitochondrial dysfunction,
insulin resistance and type 2 diabetes mellitus.
If PGC-1a is indeed a crucial factor in relation to
mitochondrial function, the question arises of why PGC-1a
is reduced in the prediabetic state?
Although it is tempting to speculate that genetic factors
underlie the reduced expression of PGC-1a in the pre-
diabetic state, the impact of environmental factors should
not be ruled out. As mentioned earlier, acute exercise
(Russell et al. 2005), as well as endurance training (Russell
et al. 2003a), can increase the expression and protein
content of PGC-1a. Whether the opposite effect, a reduc-
tion in PGC-1a as a result of physical inactivity, also
occurs is presently unknown, but it is tempting to suggest
that the low level of physical activity that characterizes
Westernized society is partly responsible for the reduction
in PGC-1a levels. In that context, the study of Mootha
et al. (2003) has observed that the reduction in OXPHOS
genes is strongly correlated with whole-body aerobic cap-
acity. Although this result can be interpreted as PGC-1a
being a determinant of oxidative capacity, it is also known
that whole-body aerobic capacity is mainly determined by
an individual’s physical activity history (Katzel et al. 2001;
Nagaya et al. 2001). Thus, the strong correlation between
OXPHOS genes and aerobic capacity may also support
the suggestion that physical (in)activity underlies the
reduction in PGC-1a and oxidative gene expression.
Very interestingly, consumption of a high-fat diet for 3 d
reduces PGC-1a protein levels by approximately 20% in
human volunteers, whereas there is a 40% reduction in
c57Bl/6J mice after 3 weeks on a high-fat diet (Sparks
et al. 2005). Again, this finding suggests that the reduction
of PGC-1a in the prediabetic state may very well be
associated with Westernized lifestyle factors. To investi-
gate whether a high fatty acid supply is indeed able to
down regulate PGC-1a a study has been conducted to
establish whether the acute elevation of plasma NEFA
during a hyperinsulinaemic euglycaemic clamp is associ-
ated with a down-regulation in the expression of skeletal
muscle genes involved in oxidative metabolism (Hoeks
et al. 2006a). Thus, when healthy volunteers receive an
infusion of Intralipid (a fat emulsion; Fresenius Kabi,
Bad Homburg, Germany) over a period of 6 h there is an
approximately 2.7-fold increase in plasma NEFA levels, a
31% decrease in insulin sensitivity and an approximately
1.6-fold increase in muscular fat content. Under these
conditions of high circulating and muscular fat content,
PGC-1a is acutely down regulated. Again, this finding
suggests that the decrease in PGC-1a expression observed
in the (pre)diabetic state may be the result of diabetogenic
environmental factors, and PGC-1a may therefore provide
a link between an unhealthy lifestyle and the development
of mitochondrial dysfunction and ultimately type 2 dia-
betes mellitus.
A role for oxidative stress in the development of
insulin resistance
Since the finding that mitochondrial function may be
impaired in the (pre)diabetic state, most studies have
focused on PGC-1a and mitochondrial biogenesis. How-
ever, mitochondrial function is not only determined
by mitochondrial biogenesis, but also by mitochondrial
quality. In the latter context, it has been shown (Kelley
et al. 2002) that mitochondria from patients with type 2
diabetes are smaller and show morphological abberations
when compared with controls, and mitochondrial area
correlates positively with insulin sensitivity. The smaller
and damaged mitochondria in skeletal muscle of patients
with diabetes also result in an impaired functional capacity
(Kelley et al. 2002). Thus, mitochondria of patients
with type 2 diabetes have a reduced electron transport
chain capacity, as measured by NADH:O2 oxidoreductase
activity, as well as a reduced citrate synthase activity
(Kelley et al. 2002).
To explain the observed mitochondrial damage, elevated
production of reactive oxygen species (ROS) and its
by-products (e.g. lipid peroxides) has been suggested. In
addition to the production of ATP, mitochondria are also
the major contributor to the production of ROS. Mito-
chondrial ROS can react rapidly with DNA, protein and
lipids, thereby leading to so-called oxidative damage.
Recent evidence points towards a causal role for ROS in
the development of insulin resistance. Thus, Houstis et al.
(2006) have found that cellular ROS levels are elevated in
two cell models of insulin resistance in which insulin
resistance is either induced by treatment with the cytokine
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TNFa or by the glucocorticoid dexamethasone. To provide
evidence for a causal relationship between the elevated
ROS levels and insulin resistance, the authors over-
expressed a variety of antioxidant genes in their model,
and it was found that the over-expression of each of these
genes could reverse the insulin resistance induced by both
TNFa and dexamethasone (Houstis et al. 2006).
Fatty acids are especially very prone to ROS-induced
oxidative damage, resulting in the formation of lipid per-
oxides, which in turn can induce damage to proteins and
DNA. Thus, accumulation of fatty acids in the vicinity of
the mitochondrial matrix, where ROS are formed, in-
creases the likelihood of lipid peroxidation. As discussed
earlier, patients with type 2 diabetes are characterized by
the accumulation of IMCL and these lipid droplets are
located close to the mitochondria. To prevent simple dif-
fusion of fatty acids into the mitochondria their entry is
regulated by the enzyme carnitine palmitoyltransferase 1,
which serves as an inward transporter of oxidizable fatty
acids. However, this system cannot completely prevent the
diffusion of fatty acid into the mitochondria. Mitochondrial
membranes consist of lipid bilayers and therefore fatty
acids can still enter the mitochondria matrix via a so-called
‘flip–flop’ mechanism over the membrane (Ho et al. 2002).
It can easily be imagined that this ‘passive diffusion’ is
more likely to occur under conditions of a high IMCL
concentration, as is the case with insulin resistance and
type 2 diabetes mellitus. Consistent with this notion,
skeletal muscle of subjects who are obese and insulin
resistant not only contains a higher amount of IMCL, but
these lipids also show a higher extent of lipid peroxidation
(Russell et al. 2003b). Potentially, these lipid peroxides
could lead to oxidative damage to mitochondrial structures
and explain the increased mitochondrial damage observed
in patients with type 2 diabetes (Kelley et al. 2002).
Mitochondrial uncoupling protein-3 to prevent
lipid-induced oxidative damage
If mitochondria are vulnerable to their own ROS and the
resulting lipid peroxides, these organelles should be
equipped with a protective mechanism. Recently, it has
been proposed (Schrauwen et al. 2006) that the mitochon-
drial uncoupling protein (UCP) 3 fulfils such a protective
role against lipid-induced oxidative damage. UCP3 was
discovered in 1997 as a human homologue of the brown
adipose tissue-specific UCP1. However, after several years
of research it became evident that in contrast to UCP1,
UCP3 has no major role in the regulation of energy meta-
bolism, but is rather involved in fatty acid metabolism. In
several physiological experiments it has been observed that
UCP3 is up regulated under conditions in which the supply
of fatty acids to the muscle exceeds the fat oxidative
capacity, such as fasting, high-fat feeding (Hesselink et al.
2003) and acute exercise (Schrauwen et al. 2002a), and in
type 2b muscle fibres (Hesselink et al. 2001). On the other
hand, UCP3 is down regulated when the fat oxidative
capacity is high, as in type 1 muscle fibres (Hesselink et al.
2001) and with endurance training (Schrauwen et al.
2005). When fatty acid supply does not match fatty acid
oxidation, fatty acids will accumulate in the cytosol and
the possibility of fatty acids entering the mitochondrial
matrix via ‘flip–flop’ will increase. Based on these find-
ings, it has been postulated (Schrauwen et al. 2001)
that UCP3 could function as a fatty acid anion exporter.
Fatty acids that ‘flip–flop’ over the inner mitochondrial
membrane will become deprotonated as a result of a proton
gradient over the inner mitochondrial membrane, resulting
in fatty acid anions. Importantly, fatty acid anions are not
able to ‘flip-flop’ back across the membrane (Ho et al.
2002), nor can they undergo b-oxidation because the
enzyme that converts long-chain fatty acids to fatty acyl-
CoA is absent in the mitochondrial matrix (Tol, 1975).
Thus, the inner mitochondrial membrane would accumu-
late fatty acid anions on the side of the mitochondrial
matrix. Moreover, these fatty acid anions could potentially
leave the inner mitochondrial membrane and accumulate
inside the mitochondrial matrix; these anions could
accumulate either dissolved in the matrix at very low
concentrations or bound to matrix-associated fatty acid-
binding proteins (Unterberg et al. 1990). In the matrix (or
at the inner side of the inner mitochondrial membrane),
these fatty acid anions would be prone to peroxidization by
ROS. As peroxidized fatty acids are highly reactive (Yagi,
1987), they could damage DNA, RNA and proteins of the
mitochondrial machinery, which are mainly present in the
mitochondrial matrix. It has been postulated (Schrauwen
et al. 2001) that UCP3 may serve as an exporter of non-
metabolizable fatty acid anions, protecting mitochondria
from oxidative damage. This hypothesis is consistent with
those postulated by other researchers, which also predict
that UCP3 is a fatty acid anion exporter (Skulachev, 1991;
Garlid et al. 1998; Jezek et al. 1998).
Subsequent to postulating this hypothesis several exper-
iments were carried out to test its validity. First, use was
made of the potential of Etomoxir to inhibit carnitine
palmitoyltransferase 1, the rate-limiting step in the mito-
chondrial uptake of fatty acyl-CoA. Healthy human sub-
jects were given Etomoxir for 36 h, while consuming a
high-fat diet to increase fatty acid supply (Schrauwen et al.
2002b). According to the hypothesis, this condition would
be one of the most formidable in which UCP3 is needed,
as both the oxidative capacity is low and the supply of fat
is high. As anticipated, there is a 67% induction of UCP3
at the protein level after only 36 h of Etomoxir treatment.
These findings have been confirmed in rats (Schrauwen
et al. 2003), where it was found that Etomoxir treatment
for 8 d results in an approximately 2-fold decrease in
carnitine palmitoyltransferase 1 activity and an approxi-
mately 2-fold increase in UCP3 protein levels.
A second study (Hoeks et al. 2003) has utilized the
unique ability of medium-chain fatty acids to pass the
mitochondrial bilayer independently of carnitine palmi-
toyltransferase 1. An important aspect of the hypothesis is
that neutral fatty acids that enter the mitochondrial matrix
cannot be oxidized because they cannot be converted to
fatty acyl-CoA inside the matrix (Kerner & Hoppel, 2000).
However, this premise is not true for medium-chain
fatty acids; these fatty acids can be activated inside the
mitochondrial matrix and do not rely on carnitine palmit-
oyltransferase 1 for mitochondrial uptake (Tol, 1975;
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Rasmussen et al. 2002). Thus, even when neutral medium-
chain fatty acids reach the mitochondrial matrix they can
be activated to fatty acyl-CoA and directed to b-oxidation
(Fujino et al. 2001). Obviously, these fatty acids do not
need to (and should not) be exported from the matrix,
eliminating a role for UCP3 in the handling of these
specific medium-chain fatty acids. Thus, there is no need
for UCP3 to control increased levels of medium-chain fatty
acids inside the matrix, in contrast to the anticipated
increase in UCP3 with a high-fat diet containing pre-
dominantly long-chain fatty acids. To test this notion, rats
were fed high-fat diets containing either long-chain fatty
acids or medium-chain fatty acids for 14 d (Hoeks et al.
2003). UCP3 protein content was found to increase 2-fold
on feeding the long-chain fatty acid high-fat diet, but to be
unaffected by feeding the medium-chain fatty acid high-fat
diet. Furthermore, this differential UCP3 response is
accompanied by a similar rise in plasma NEFA levels and
also cannot be explained by a PPAR effect, as other PPAR-
responsive genes are similarly affected by the diets (Hoeks
et al. 2003). Again, these data support the hypothesis that
UCP3 is involved in the export from the mitochondrial
matrix of fatty acids that cannot be metabolized.
According to the hypothesis UCP3 prevents the accu-
mulation of fatty acid anions inside the mitochondrial
matrix and membranes, which otherwise would be vulner-
able to ROS-induced oxidative damage, resulting in lipid
peroxides. It can therefore be predicted that lack of UCP3
would lead to increased lipid peroxide levels and/or
oxidative damage. Indeed, mice lacking UCP3 are charac-
terized by increased levels of lipid peroxides (Hoeks et al.
2006b) and damage to mitochondrial proteins (Brand
et al. 2002). Very interestingly, it has recently been shown
(Echtay et al. 2003) that UCP3 can be activated by
4-hydroxy-2-nonenal, an important byproduct of lipid per-
oxidation, suggesting that a negative feedback loop is
involved in the regulation of mitochondrial lipid peroxide
production, whereby elevated lipid peroxide levels activate
UCP3, thereby limiting further accumulation of these toxic
lipid products.
Uncoupling protein 3 and type 2 diabetes mellitus
The increased content of muscular fat, the higher extent of
lipid peroxidation of these fats and the observed mito-
chondrial damage in patients who are insulin resistant
and/or patients with type 2 diabetes could be linked if the
previously mentioned negative feedback loop is disturbed.
Although the possibility of a link clearly needs further
investigation, it is intriguing to note that patients with type
2 diabetes, as well as subjects with impaired glucose
tolerance who are often considered as being ‘prediabetic’,
have a 50% reduction in UCP3 protein levels (Schrauwen
et al. 2006). It is tempting to speculate that in patients with
type 2 diabetes the reduction in UCP3 is a pathological
condition in which low levels of UCP3 fail to sufficiently
protect mitochondria against lipid-induced mitochondrial
damage, indicating a defective feedback mechanism
between lipid peroxides and mitochondrial uncoupling.
This notion is further supported by the finding (Mensink
et al. 2006) that in subjects who are prediabetic (i.e.
impaired glucose tolerant) a lifestyle intervention pro-
gramme results in a 2-fold increase in UCP3 protein after
1 year, thereby restoring UCP3 to normal physiological
levels. In addition, UCP3 protein content is also restored in
patients with type 2 diabetes after 1 year of an endurance
training programme, in parallel with improvement in
insulin sensitivity (Mensink et al. 2006). Finally, it has
recently been shown (Schrauwen et al. 2006) that the
insulin-sensitizing agent Rosiglitazone up regulates the
protein content of UCP3 in skeletal muscle of patients with
type 2 diabetes, in parallel with an improved oxidative
capacity, mitochondrial succinate dehydrogenase activity
and muscular insulin sensitivity. In addition, evidence for
an important role for UCP3 in the aetiology of type 2
diabetes also comes from the recent finding that genetic
variation in the UCP3 gene is associated with the 10- and
15-year risk for developing type 2 diabetes mellitus (Gable
et al. 2006). Obviously, these findings in human subjects
do not yet prove that reduced levels of UCP3 are causally
related to the development of lipid-induced oxidative
damage and insulin resistance, and further studies are
needed to prove a functional role for UCP3 in type 2
diabetes.
Conclusion
The consumption of high-fat diets is associated with an
excessive storage of fatty acids in white adipose tissue, but
also in non-adipose tissues such as liver, heart and skeletal
muscle. Muscular fat accumulation is strongly associated
with insulin resistance, especially when a high muscular fat
content is accompanied by a low mitochondrial oxidative
capacity, as in patients with type 2 diabetes. The tran-
scription factor PGC-1a, which is involved in mitochon-
drial biogenesis, has been shown to be reduced in patients
with type 2 diabetes. Recent data indicate a role for phy-
sical inactivity and high dietary fat intake in the reduction
of PGC-1a. In addition to a putative reduction in
mitochondrial biogenesis, patients with diabetes display
increased mitochondrial damage. Such damage could be a
result of the detrimental effects of ROS produced in the
mitochondria. Fat accumulation inside muscle cells may
lead to the entry of fatty acids into mitochondria where
they are prone to ROS-induced peroxidation. In turn, these
lipid peroxides may damage mitochondria and cause a
further deterioration in oxidative capacity. UCP3 may play
an important role in the protection of mitochondria against
these lipid peroxides, by exporting fatty acid anions and/or
peroxides from the mitochondrial matrix. UCP3 is activ-
ated by lipid peroxides, which suggests a negative feed-
back loop that limits lipid-induced oxidative damage. Of
note, UCP3 protein levels are decreased by 50% in patients
with type 2 diabetes mellitus as well as in subjects who
are ‘prediabetic’ compared with age- and BMI-matched
controls. This finding may suggest that the negative feed-
back loop is indeed disturbed in pre-diabetes, and ulti-
mately could lead to lipid-induced mitochondrial damage
and insulin resistance. Interestingly, insulin-sensitizing
interventions such as treatment with Rosigilitazone or a
lifestyle intervention restore UCP3 levels to control values.
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